Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 464

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 464
---
1% of the total outstanding common stock. |

- 315 -

| (1) | Based solely on a Schedule 13D/A filed with the SEC on December 23, 2024, the beneficial ownership shown                                                                                                                                           
 above consists of (i) 2,849,402 shares of common stock that are held by Avoro Capital Advisors LLC (“Avoro Capital”) and (ii) 622,350 shares of common stock that are held by Avoro Ventures Fund L.P. (“Avoro Ventures Fund”), an                 
 investment fund managed by Avoro Ventures LLC (“Avoro Ventures”). According to the Schedule 13D/A, Avoro Capital has sole voting power and sole dispositive power with regard to 2,849,402 shares of common stock and Avoro Ventures has sole      
 dispositive power with regard to 622,350 shares of common stock. Behzad Aghazadeh, a director of the Company, is the portfolio manager and controlling person at Avoro Capital and Avoro Ventures. The principal business address of each of Avoro 
 Capital and Mr. Aghazadeh is 110 Greene Street, Suite 800, New York, NY 10012.                                                                                                                                                                     |

| (2) | Based solely on a Schedule 13D filed with the SEC on January 19, 2025, the beneficial ownership shown above                                                                                                                                         
 consists of (i) 1,572,698 shares held by Acuta Capital Fund, L.P. (“Acuta Capital”) and (ii) 276,704 shares held by Acuta Opportunity Fund, L.P. (“Acuta Opportunity Fund”). Acuta Capital Partners, LLC (“Acuta Partners”)                         
 is a general partner of each of Acuta Capital and Acuta Opportunity Fund. According to the Schedule 13D, Acuta Partners has shared voting power and shared dispositive power with regard to 1,849,402 shares of common stock. Dr. Dalal, a director 
 of the Company, is the Chief Investment Officer and Managing Member of Acuta Partners. Dr. Dalal has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and    
 Dr. Dalal disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein. The principal business address of each of Acuta Capital is 
 c/o Acuta